Orchid Pharma shares slipped more than 3% in early trade on February 12 (IST) after the company reported a sharp deterioration in its Q3 consolidated earnings on a year-on-year (YoY) basis. Weak operating performance and a swing to net loss weighed on investor sentiment.
As of 9:27 AM (IST), the stock was trading near ₹660 levels after opening at ₹679.45, compared to the previous close of ₹689.80. During the session, the stock touched an intraday low of ₹660.00 and a high of ₹685.40. The counter remains significantly below its 52-week high of ₹1,325.00, while staying above the 52-week low of ₹603.80.
Orchid Pharma Q3 Results: Key Financial Highlights (Consolidated, YoY)
For the quarter under review, revenue declined 4.6% to ₹207 crore, compared to ₹217 crore in the same period last year.
Operating performance saw a steep drop, with EBITDA plunging 94.2% to ₹1.5 crore from ₹26.4 crore a year ago. EBITDA margin contracted sharply by 1,140 basis points to 0.7%, versus 12.1% in the corresponding quarter of the previous fiscal.
At the bottom line level, Orchid Pharma reported a net loss of ₹12.6 crore, compared to a net profit of ₹20.8 crore in the year-ago period, marking a significant reversal in profitability.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.